Neonatal Partial Exchange Transfusion for Polycythaemia
Calculates volume of blood to exchange with normal saline to reduce haematocrit in neonatal polycythaemia. Polycythaemia defined as venous Hct ≥65% (Hb ≥220 g/L). Treatment indicated if symptomatic or Hct ≥70%.
Score interpretation
Exchange volume ≤15 mL — small partial exchange required
→ Perform partial exchange transfusion: withdraw calculated volume from umbilical venous catheter (UVC) or peripheral IV and replace with equal volume of 0.9% normal saline over 30–60 minutes; monitor SpO2, HR, glucose, temperature throughout; recheck Hct 4–6 hours post-procedure; ensure blood cultures obtained before if infection concern
Exchange volume 16–50 mL — standard partial exchange
→ Access via UVC preferred; aliquots of 5–10 mL exchange over 30–60 minutes; monitor vital signs, glucose, calcium; recheck Hct at 4–6 hours; if symptomatic polycythaemia (plethora, jitteriness, poor feeding, hypoglycaemia, respiratory distress): exchange is indicated regardless of Hct; document pre- and post-exchange bloods; neonatologist to supervise procedure
Exchange volume >50 mL — large exchange; senior neonatologist input required
→ Senior neonatologist review before proceeding; confirm diagnosis (use central/venous Hct — capillary samples overestimate Hct); ensure appropriate vascular access; consider splitting into two smaller exchanges if volume very large; watch for NEC risk post-exchange (avoid early enteral feeds for 4–6 hours); neonatal intensive care monitoring; document all procedures meticulously
Interpretation bands for the Neonatal Partial Exchange. Apply clinical judgement and local guidance.
References
- Black VD, Lubchenco LO. Neonatal polycythemia and hyperviscosity. Pediatr Clin North Am. 1982;29(5):1137–1148.
- British Association of Perinatal Medicine. Guideline on polycythaemia and hyperviscosity in neonates. BAPM. 2011.
Related
Curated clinical cross-links plus same-class fallbacks.
- Celiprolol hydrochloride · Cardioselective beta-blocker (β1 + β2 partial agonist)
- Buprenorphine · Opioid partial agonist (μ-receptor partial agonist, κ-antagonist)
- Colestyramine (Cholestyramine) · Bile Acid Sequestrant / Ion Exchange Resin
- Rituximab (Haematology) · Anti-CD20 Monoclonal Antibody
- Rozanolixizumab · Neonatal Fc receptor (FcRn) antagonist
- Efgartigimod alfa · Neonatal Fc receptor (FcRn) blocker
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.